CD34 Selection Using the Automated CliniMACS Prodigy
Status:
Not yet recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell
boost or an additional hematopoietic stem cell transplantation procedure. In such settings
standard immune suppression strategies are avoided due to their myelosuppressive nature.
Therefore those patients are at increased risk of graft versus host disease, and the infusion
of a CD34 selected graft would reduce such a risk. The infusion of CD34 selected graft using
CliniMACS plus is currently FDA FDA-approved indication for acute myeloid leukemia. However,
the use of the Prodigy would streamline the processing, in terms of hands-off procedure,
allowing to provision of this product to the patients without strains on the cell therapy lab
team. This procedure has been demonstrated safe and effective in several single-center
studies and is currently in advanced phase investigation in several studies for malignant and
non-malignant conditions.